Two phase II trials, NEONIPIGA and INFINITY, were designed to validate the use of a perioperative strategy with dual ICIs in patients with dMMR/MSI-H gastric cancer; both trials revealed high pCR rates after neoadjuvant treatment with anti–PDL1 and anti-cytotoxic T-lymphocyte–associated protein 4 (CTLA4) antibodies [41,42]. This evidence concerns the gene CTLA4 and gastric cancer.